↓ Skip to main content

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis

Overview of attention for article published in Journal of Gastrointestinal Surgery, October 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

policy
2 policy sources
twitter
1 X user
patent
4 patents

Citations

dimensions_citation
162 Dimensions

Readers on

mendeley
85 Mendeley
Title
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
Published in
Journal of Gastrointestinal Surgery, October 2015
DOI 10.1007/s11605-015-2995-9
Pubmed ID
Authors

Giorgi Nadiradze, Urs Giger-Pabst, Juergen Zieren, Dirk Strumberg, Wiebke Solass, Marc-André Reymond

Abstract

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer (GC) are presented. Retrospective analysis: Sixty PIPAC were applied in 24 consecutive patients with PM from GC. 67 % patients had previous surgery, and 79 % previous platinum-based systemic chemotherapy. Mean Peritoneal Carcinomatosis Index (PCI) of 16 ± 10 and 18/24 patients had signet-ring GC. Cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) were given for 30 min at 37 °C and 12 mmHg at 6 week intervals. Outcome criteria were survival, adverse events, and histological tumor response. Median follow-up was 248 days (range 105-748), and median survival time was 15.4 months. Seventeen patients had repeated PIPAC, and objective tumor response was observed in 12 (12/24 = 50 %): no vital tumor cells = 6, major pathological response = 6, minor response = 3. Postoperative adverse events > CTCAE 2 were observed in 9 patients (9/24, 37.5 %). In 3/17 patients, a later PIPAC could not be performed due to non-access. Two patients (ECOG 3 and 4) died in the hospital due to disease progression. PIPAC with low-dose cisplatin and doxorubicin was safe and induced objective tumor regression in selected patients with PM from recurrent, platinum-resistant GC. First survival data are encouraging and justify further clinical studies in this indication.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 1%
Unknown 84 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 13%
Other 10 12%
Student > Ph. D. Student 10 12%
Student > Postgraduate 8 9%
Student > Doctoral Student 6 7%
Other 15 18%
Unknown 25 29%
Readers by discipline Count As %
Medicine and Dentistry 39 46%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Biochemistry, Genetics and Molecular Biology 3 4%
Engineering 2 2%
Linguistics 1 1%
Other 4 5%
Unknown 30 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#2,295,486
of 25,608,265 outputs
Outputs from Journal of Gastrointestinal Surgery
#90
of 2,502 outputs
Outputs of similar age
#31,940
of 295,823 outputs
Outputs of similar age from Journal of Gastrointestinal Surgery
#1
of 59 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,502 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,823 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.